News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,091 Results
Type
Article (734)
Company Profile (19)
Press Release (12338)
Section
Business (4481)
Career Advice (16)
Deals (650)
Drug Delivery (2)
Drug Development (2328)
Employer Resources (2)
FDA (205)
Job Trends (271)
News (7205)
Policy (377)
Tag
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (2)
2026 Bio NC Standard (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (1)
Academia (37)
Adcomms (3)
Allergies (5)
Alliances (1213)
ALS (1)
Alzheimer's disease (10)
Antibody-drug conjugate (ADC) (9)
Approvals (202)
Artificial intelligence (4)
Bankruptcy (4)
Best Places to Work (218)
BIOSECURE Act (5)
Biosimilars (1)
Biotechnology (15)
Bladder cancer (1)
Cancer (58)
Cardiovascular disease (6)
Career advice (10)
CAR-T (9)
Cell therapy (30)
Clinical research (1784)
Collaboration (31)
Compensation (17)
COVID-19 (102)
CRISPR (4)
C-suite (11)
Cystic fibrosis (1)
Data (51)
Diabetes (3)
Diagnostics (31)
Drug discovery (2)
Earnings (1410)
Editorial (1)
Employer resources (2)
Events (2411)
Executive appointments (37)
FDA (232)
Featured Employer (2)
Funding (29)
Gene editing (9)
Gene therapy (19)
GLP-1 (17)
Government (44)
Guidances (1)
Healthcare (386)
Immunology and inflammation (4)
Infectious disease (103)
Inflammatory bowel disease (7)
Intellectual property (4)
Interviews (3)
IPO (358)
Job creations (61)
Job search strategy (10)
Kidney cancer (1)
Labor market (2)
Layoffs (13)
Legal (64)
Liver cancer (1)
Lung cancer (6)
Lymphoma (11)
Machine learning (1)
Management (1)
Manufacturing (9)
MASH (1)
Medical device (63)
Medtech (63)
Mergers & acquisitions (305)
Metabolic disorders (7)
Neurodegenerative disease (5)
Neuroscience (19)
NextGen: Class of 2025 (138)
Non-profit (19)
Northern California (103)
Now hiring (1)
Obesity (3)
Opinion (1)
Ovarian cancer (1)
Pain (6)
Pancreatic cancer (1)
Parkinson's disease (3)
Patents (10)
Patient recruitment (3)
People (1683)
Phase I (805)
Phase II (871)
Phase III (524)
Pipeline (32)
Policy (8)
Postmarket research (25)
Preclinical (271)
Press Release (1)
Prostate cancer (2)
Radiopharmaceuticals (2)
Rare diseases (7)
Real estate (112)
Recruiting (1)
Regulatory (317)
Reports (2)
Research institute (62)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (9)
Series B (2)
Service/supplier (1)
Southern California (103)
Special edition (1)
Spinal muscular atrophy (1)
Sponsored (2)
Startups (104)
Supply chain (2)
United States (651)
Vaccines (11)
Weight loss (1)
Date
Today (6)
Last 7 days (27)
Last 30 days (70)
Last 365 days (942)
2025 (298)
2024 (1025)
2023 (1263)
2022 (1597)
2021 (1628)
2020 (1242)
2019 (736)
2018 (543)
2017 (663)
2016 (546)
2015 (592)
2014 (397)
2013 (340)
2012 (293)
2011 (296)
2010 (310)
Location
Africa (14)
Asia (1075)
Australia (89)
California (281)
Canada (77)
China (21)
Colorado (2)
Connecticut (8)
Delaware (5)
Europe (1264)
Florida (18)
Idaho (1)
Illinois (5)
India (1)
Indiana (1)
Japan (3)
Maryland (47)
Massachusetts (123)
Michigan (2)
Minnesota (4)
New Jersey (46)
New Mexico (1)
New York (23)
North Carolina (14)
Northern California (103)
Oklahoma (1)
Pennsylvania (47)
South America (9)
Southern California (103)
Texas (21)
Utah (2)
Washington D.C. (2)
Washington State (9)
Wisconsin (1)
13,091 Results for "salubris biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure
January 22, 2025
·
4 min read
Drug Development
Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
Salubris Biotherapeutics, Inc. today announced a new capital infusion of $35 million to fund continued research and development of clinical and pre-clinical programs.
April 22, 2024
·
6 min read
BioCapital
Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
Salubris Biotherapeutics, Inc. announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.
March 28, 2023
·
4 min read
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
BioCapital
Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced that positive initial data from the first-in-human study evaluating JK08 in adults with solid tumors were presented in a poster session during the European Society of Medical Oncology Annual Congress 2023.
October 23, 2023
·
3 min read
Drug Development
Salubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the completed Phase 1b study of JK07 in patients with HFrEF.
October 9, 2023
·
4 min read
Press Releases
YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China
August 27, 2024
·
4 min read
Press Releases
Interius BioTherapeutics to Present at Upcoming Scientific Meetings
April 17, 2025
·
2 min read
Press Releases
Adolore BioTherapeutics to Present at Festival of Biologics USA 2025
April 24, 2025
·
3 min read
Drug Development
Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress
Salubris Biotherapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, announced positive updated results from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction.
May 20, 2023
·
5 min read
1 of 1,310
Next
